Anti-Rh(c), "Little C," Isoimmunization: The Role of rHuEpo in Preventing Late Anemia

Antonio Alberto Zuppa; Valentina Cardiello; Giovanni Alighieri; Francesco Cota; Annamaria D'Antuono; R Riccardi; P Catenazzi; C. Romagnoli

Anti-Rh(c), "Little C," Isoimmunization: The Role of rHuEpo in Preventing Late Anemia

Antonio Alberto Zuppa, Valentina Cardiello, Giovanni Alighieri, Francesco Cota, Annamaria D'Antuono, R Riccardi, P Catenazzi, C. Romagnoli

Università Cattolica del Sacro Cuore

Research output: Contribution to journal › Article

Abstract

The overall prevalence of non-Rh-D isoimmunization seems to lie between 0.15% and 1.1%. Anti-Rh(c) alloimmunization, "little c," occurs in 0.07% of pregnancies and shows a quite broad clinical presentation. Late anemia is a frequent problem occurring in the setting of isoimmunization. It occurs more frequently after intrauterine blood transfusions or exsanguinotransfusion, and it can be thought as a hyporegenerative anemia. The authors describe the use of human recombinant erythropoietin in preventing late anemia in a case of anti-Rh(c) isoimmunization. The use of human recombinant erythropoietin is a valid tool for preventing late-onset anemia due to either anti-Rh-D or non-anti-Rh-D isoimmunization.

Original language	English
Pages (from-to)	N/A-N/A
Journal	JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
Publication status	Published - 2012

Keywords

isoimmunization
rHuEpo

Cite this

@article{4a02726d8ea041fc98623a86df59e7b2,

title = "Anti-Rh(c), {"}Little C,{"} Isoimmunization: The Role of rHuEpo in Preventing Late Anemia",

abstract = "The overall prevalence of non-Rh-D isoimmunization seems to lie between 0.15% and 1.1%. Anti-Rh(c) alloimmunization, {"}little c,{"} occurs in 0.07% of pregnancies and shows a quite broad clinical presentation. Late anemia is a frequent problem occurring in the setting of isoimmunization. It occurs more frequently after intrauterine blood transfusions or exsanguinotransfusion, and it can be thought as a hyporegenerative anemia. The authors describe the use of human recombinant erythropoietin in preventing late anemia in a case of anti-Rh(c) isoimmunization. The use of human recombinant erythropoietin is a valid tool for preventing late-onset anemia due to either anti-Rh-D or non-anti-Rh-D isoimmunization.",

keywords = "isoimmunization, rHuEpo, isoimmunization, rHuEpo",

author = "Zuppa, {Antonio Alberto} and Valentina Cardiello and Giovanni Alighieri and Francesco Cota and Annamaria D'Antuono and R Riccardi and P Catenazzi and C. Romagnoli",

year = "2012",

language = "English",

pages = "N/A--N/A",

journal = "JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY",

issn = "1077-4114",

publisher = "Lippincott, Williams & Wilkins:530 Walnut Street:Philadelphia, PA 19106:(800)638-3030, (301)223-2300, EMAIL: [email protected], INTERNET: http://www.lww.com, Fax: (301)223-2320, (301)223-2320",

}

TY - JOUR

T1 - Anti-Rh(c), "Little C," Isoimmunization: The Role of rHuEpo in Preventing Late Anemia

AU - Zuppa, Antonio Alberto

AU - Cardiello, Valentina

AU - Alighieri, Giovanni

AU - Cota, Francesco

AU - D'Antuono, Annamaria

AU - Riccardi, R

AU - Catenazzi, P

AU - Romagnoli, C.

PY - 2012

Y1 - 2012

N2 - The overall prevalence of non-Rh-D isoimmunization seems to lie between 0.15% and 1.1%. Anti-Rh(c) alloimmunization, "little c," occurs in 0.07% of pregnancies and shows a quite broad clinical presentation. Late anemia is a frequent problem occurring in the setting of isoimmunization. It occurs more frequently after intrauterine blood transfusions or exsanguinotransfusion, and it can be thought as a hyporegenerative anemia. The authors describe the use of human recombinant erythropoietin in preventing late anemia in a case of anti-Rh(c) isoimmunization. The use of human recombinant erythropoietin is a valid tool for preventing late-onset anemia due to either anti-Rh-D or non-anti-Rh-D isoimmunization.

AB - The overall prevalence of non-Rh-D isoimmunization seems to lie between 0.15% and 1.1%. Anti-Rh(c) alloimmunization, "little c," occurs in 0.07% of pregnancies and shows a quite broad clinical presentation. Late anemia is a frequent problem occurring in the setting of isoimmunization. It occurs more frequently after intrauterine blood transfusions or exsanguinotransfusion, and it can be thought as a hyporegenerative anemia. The authors describe the use of human recombinant erythropoietin in preventing late anemia in a case of anti-Rh(c) isoimmunization. The use of human recombinant erythropoietin is a valid tool for preventing late-onset anemia due to either anti-Rh-D or non-anti-Rh-D isoimmunization.

KW - isoimmunization

KW - rHuEpo

KW - isoimmunization

KW - rHuEpo

UR - http://hdl.handle.net/10807/39803

M3 - Article

SN - 1077-4114

SP - N/A-N/A

JO - JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

JF - JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

ER -

Anti-Rh(c), "Little C," Isoimmunization: The Role of rHuEpo in Preventing Late Anemia

Abstract

Keywords

Other files and links

Fingerprint

Cite this